InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Monday, 06/22/2020 4:58:55 PM

Monday, June 22, 2020 4:58:55 PM

Post# of 195
News just keeps coming in:

FDA accepts Myovant application for relugolix for prostate cancer
The FDA accepts for review Myovant Sciences' (MYOV +2.8%) marketing application for relugolix for the treatment of advanced prostate cancer. The agency's action date is December 20.

On June 1, it filed a U.S. application for a relugolix combo pill for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
https://seekingalpha.com/news/3584919-fda-accepts-myovant-application-for-relugolix-for-prostate-cancer?v=1592837908